Hyperlink (09989.HK) held a board meeting on April 29 to consider and approve the first quarter results
On April 16, GLONGHUI (09989.HK) announced that the company will hold a board meeting on April 29, 2024 (Monday) to consider and approve the Group's first quarter results for the three months ended March 31, 2024 and their publication.
Shenzhen Hepalink Receives Thai Approval for Blood Clot Drug Exarane
Shenzhen Hepalink Pharmaceutical Group's (HKG:9989, SHE:002399) enoxaparin sodium injection, Exarane, has been approved by the Thailand Food and Drug Administration for sales in the market, a Tuesday
Hipry (09989.HK): EXARANE obtains approval from Thailand
On April 2, Gelonghui (09989.HK) announced that Exarane (one of the Group's leading drugs for enoxaparin sodium injections) produced by its wholly-owned subsidiary Shenzhen Tiandao Pharmaceutical Co., Ltd., has been approved for marketing by the Thai Food and Drug Administration. The announcement stated that with this approval, the ennoxaparin sodium formulation representing the Group Hypree will be sold in the Thai market, which will further increase the global market share of the Group's enoxaparin sodium preparations. The Group believes that this approval is another important achievement in implementing the international layout of the Group's pharmaceutical business, once again proving that the Group has entered overseas markets
Hapley (09989): A total of 1 billion yuan in preparation for impairment in 2023
Hyperlink (09989) issued an announcement that Shenzhen Haipuri Pharmaceutical Group Co., Ltd. (hereinafter referred to as the “Company”)...
Hapley (09989) plans to carry out foreign exchange derivatives transactions for hedging purposes with a total value of no more than 350 million US dollars
Hipry (09989) issued an announcement. In order to reduce foreign exchange risk and enhance financial stability, Shenzhen Haipuri Pharmaceutical Group...
Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Is Making Moderate Use Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Hapley (002399.SZ) announced its 2023 annual results, with a net loss of 783 million yuan, changing from profit to loss
According to the Zhitong Finance App, Hapley (002399.SZ) released its 2023 annual report. The company's operating income was 5.446 billion yuan, down 23.94% from the previous year; net loss attributable to shareholders of listed companies was 783 million yuan, which changed from profit to loss; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 780 million yuan, which changed from profit to loss; basic loss per share was 0.5338 yuan/share. During the reporting period, the company's heparin industry chain business achieved sales revenue of RMB 4.287 billion, a year-on-year decrease of 27.15%. Formulation sales remained stable, achieving sales revenue of RMB 2,979 billion
Hyperion (002399.SZ): Enoxaparin sodium injection obtained New Zealand drug registration approval
Haipuri (002399.SZ) announced that the company's wholly-owned subsidiary, Shenzhen Tiandao Pharmaceutical Co., Ltd. (abbreviated as “Tiandao...
海普瑞:截至二零二三年十二月三十一日止年度全年業績公告
Hyperlink (09989.HK) will hold a board meeting on March 28 to approve the full year results
On March 15, GLONGHUI (09989.HK) announced that the company will hold a board meeting on March 28, 2024 to approve the annual results and announcements of the company and its subsidiaries for the year ended December 31, 2023, and to consider the payment of a final dividend (if any).
HEPALINK: DATE OF BOARD MEETING
Hapley (09989) received a total of 89.8096 million yuan in advance payments from the controlling shareholder
According to the Zhitong Finance App, Hapley (09989) announced that Techdow Pharma Italy S.R.L., a wholly-owned subsidiary of the company, was involved in telecom fraud by a criminal group. The amount involved was more than 11.7 million euros. In order to protect the interests of the company and investors, Li Li, the controlling shareholder of the company, promised on February 3, 2024 that the company would advance capital equivalent to no more than 11.74 million euros in advance to the company. On March 14, 2024, the company received advance payments from Mr. Li through Shenzhen Leren Technology Co., Ltd., totaling RMB 8980.9
As a result of electronic fraud of more than 10 million euros, Hapry (002399.SZ) received an advance payment of 89.8096 million yuan from the controller
Hapley (002399.SZ) issued an announcement, and on January 15, 2024, the company issued “Regarding the importance of subsidiaries...
Damo: Maintaining Hypry's (09989) “In sync with the market” rating, the target price was reduced to HK$3.9
Damo cut Hapley's profit in 2024-30, which is expected to decline by 11%-12% due to declining sales and gross margins in the API and formulation divisions.
Hyperion (09989) fell 2.40% and now reports 2.450 yuan, a 52-week low
As of 16:08, Hapry (09989) is down 2.40% from yesterday's closing price and is now reporting a 52-week low of $2,450; the trading volume is 596,000 shares, with a turnover of HK$1,449,800.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE:002399) Stocks Pounded By 35% But Not Lagging Market On Growth Or Pricing
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE:002399) shareholders that were waiting for something to happen have been dealt a blow with a 35% share price drop in the last month. Instead o
Shenzhen Hepalink Forecasts Loss in 2023; Shares Slide 4%
Shenzhen Hepalink Pharmaceutical Group (HKG:9989, SHE:002399) forecasts it will swing to a loss of between 647 million yuan to 924 million yuan from a profit of 727.1 million yuan in the year-ago peri
Shenzhen Hepalink Flags Provisions of Up to 950 Million Yuan; Shares Fall 4%
Shenzhen Hepalink Pharmaceutical Group (HKG:9989, SHE:002399) flagged provisions for a decline in inventories of between 750 million yuan and 950 million yuan, a Tuesday filing said. The resulting pro
Changes in Hong Kong stocks | Hapley (09989) fell nearly 4% and is expected to have a net loss of up to 924 million yuan last year from profit to loss
Hapley (09989) fell nearly 4%. As of press release, it was down 3.79% to HK$2.54, with a turnover of HK$1,945,900.
Hapley (09989) is preparing for an inventory price drop of 750 million yuan to 950 million yuan for the 2023 fiscal year
Hapley (09989) issued an announcement. The company is in accordance with China's “Enterprise Accounting Standard No. 1 - Inventory” and corporate accounting policies...
No Data